Let's compare your statements on Clinuvel who are valued at just $300 Million while making close to $40 Million NPAT annually to Disc who are losing $1 Million every two days while being valued at $2.5 Billion!
- One product (scenesse) Zero approved Products at Disc - approx 400-500 patients Zero patients - market saturation Hoping to enter the 'saturated' EPP market with their lead product when we don't even know if it works for EPP - market competition around the corner Disc is the competition who are 'around the corner' but have no blockbusters in phase 3 - no ip I believe Disc have to pay Royalties if successful to whoever they purchased their IP from - no invest in R&D Disc running no blockbuster Phase 3s but burning an extraordinary amount of cash - no insider buyingsEnormous insider selling at Disc - could someone post the amounts who know SEC filings
Interesting risk/reward paradox with these two.
All IMO DYOR
CUV Price at posting:
$10.71 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)